Bessemer Group
ANIK icon

Bessemer Group’s Anika Therapeutics ANIK Stock Holding History

Bessemer Group’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-50
Closed -$1K – 2448
2024
Q3 		$1K Buy
+50
New +$1.3K ﹤0.01% 2319
2022
Q3 		– Sell
-135
Closed -$3K – 2014
2022
Q2 		$3K Hold
135
– – ﹤0.01% 1647
2022
Q1 		$3K Buy
+135
New +$4.12K ﹤0.01% 1662
2020
Q3 		– Sell
-118
Closed -$4K – 1346
2020
Q2 		$4K Buy
+118
New +$3.89K ﹤0.01% 1576
2016
Q4 		– Sell
-412
Closed -$20K – 1932
2016
Q3 		$20K Buy
+412
New +$20.4K ﹤0.01% 1367

Other funds holding ANIK

TI
Trigran Investments Northbrook, Illinois $545M AUM 56.2% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AFA
Alta Fundamental Advisers New York $333M AUM 102.25% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
CM
Capital Management Glen Allen, Virginia $666M AUM 17.17% 1-Year Est. Return

Bessemer Group's ANIK Position: Q4 2024 in Review

Bessemer Group sold out of Anika Therapeutics (ANIK) in Q4 2024, closing a stake of 50 shares — an estimated $1K sold.

Bessemer Group first reported a position in ANIK in Q3 2016 and held it in 5 quarters. The position peaked at $20K in Q3 2016. 109 funds tracked by Wall St. Rank hold ANIK as of Q4 2024.

  • Bessemer Group reported no remaining Anika Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Bessemer Group sold 50 Anika Therapeutics shares in Q4 2024, an estimated $1K.
  • Bessemer Group first reported a position in Anika Therapeutics in Q3 2016 and held it in 5 quarters.
  • Bessemer Group's Anika Therapeutics position peaked at $20K in Q3 2016.
  • 109 funds tracked by Wall St. Rank held Anika Therapeutics as of Q4 2024.

Based on Bessemer Group's 13F filing for Q4 2024, filed 13 Feb 2025.